Show simple item record

Authordc.contributor.authorNolan, Terry 
Authordc.contributor.authorO'Ryan Gallardo, Miguel 
Authordc.contributor.authorWassil, James 
Authordc.contributor.authorAbitbol, Véronique 
Authordc.contributor.authorDull, Peter 
Admission datedc.date.accessioned2015-12-04T17:45:00Z
Available datedc.date.available2015-12-04T17:45:00Z
Publication datedc.date.issued2015
Cita de ítemdc.identifier.citationVaccine 33 (2015) 4437–4445en_US
Identifierdc.identifier.otherDOI: 10.1016/j.vaccine.2015.06.011
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/135492
General notedc.descriptionArtículo de publicación ISIen_US
Abstractdc.description.abstractVaccination programs employing capsular-based meningococcal vaccines have proved successful in a variety of settings globally since first introduced over 40 years ago. Similar successes have been demonstrated using meningococcal vaccines for use against serogroup B (MenB) outbreak strains but the diversity of MenB strains has limited vaccine use outside targeted geographic regions. MenB continues to be a significant cause of outbreaks in adolescents and young adults, as recently demonstrated in university settings in the US (Princeton, New Jersey and Santa Barbara, California) and has the potential for hyperendemic disease levels such as currently experienced in Quebec and the United Kingdom. In adolescents, increased endemic disease rates and outbreak potential are likely associated with social behaviors putting individuals at risk for carriage acquisition and may explain regional and temporal variations in epidemiology. A protein-based, multi-component MenB vaccine (4CMenB) is currently licensed for use in 37 countries including EU/EEA countries, Australia, Canada, Chile, Colombia, Uruguay, and the US. In this article we review the most recent clinical trial data with 4CMenB with a focus on adolescents and young adults. The vaccine appears to have an acceptable safety profile and is well-tolerated in adolescents and young adults while providing robust, persistent levels of bactericidal antibodies considered protective for each of the four antigenic components of the vaccine. With the recent availability of this vaccine, health care providers have the first comprehensive opportunity to control meningococcal disease, a highly disruptive public health problem with a disproportionate impact on adolescents and young adults.en_US
Patrocinadordc.description.sponsorshipNovartis Vaccines and Diagnosticsen_US
Lenguagedc.language.isoenen_US
Publisherdc.publisherElsevieren_US
Type of licensedc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Keywordsdc.subjectMeningitis--En adolescenciaen_US
Keywordsdc.subjectVacuna contra el meningococo Ben_US
Keywordsdc.subjecten_US
Keywordsdc.subjecten_US
Keywordsdc.subjecten_US
Keywordsdc.subjecten_US
Títulodc.titleVaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adultsen_US
Document typedc.typeArtículo de revista


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 Chile
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 Chile